BioMedNewsBreaks

WednesdaySep 28, 2022 11:37 am

BioMedNewsBreaks – Universal Ibogaine Inc. (TSX.V: IBO) Featured in ‘Psychedelics Tonight’ Docuseries

Universal Ibogaine (TSX.V: IBO) (“UI”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, announced it has been featured in a documentary series, which was co-produced by Kyle Buller and Joe Moore of Psychedelics Today in partnership with ALTRD.TV. Entitled Psychedelics Tonight, the docuseries provides information on the history and future potential of several psychedelic compounds including iboga and ibogaine. The first episode of the series aired on Monday, Sept. 26, 2022. “We are excited to see a growing variety of media channels pick up the story of ibogaine, to help educate the public and the…

Continue Reading

TuesdaySep 27, 2022 3:06 pm

BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Issues Corporate Update Following Reverse Stock Split, Closing of $20M Public Offering

Aditxt (NASDAQ: ADTX) is a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system. The company today provided shareholders with a corporate update following the completion of a reverse stock split and closing of a previously announced $20 million public offering. “Aditxt’s key to success is multifaceted and tied to the success of each of the company’s programs, which currently include AditxtScore(TM), Adimune(TM) and Adivir(TM). The successful completion of the reverse stock split and the closing of our public offering were critical to continuing the progress within each of these programs toward commercialization, and…

Continue Reading

TuesdaySep 27, 2022 2:30 pm

BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Enters Agreement to Obtain Novel Catalog of Psychedelic-Based Compounds

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), and its wholly owned subsidiary, Cybin IRL Limited, have signed a deal with Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) to acquire an exclusive license to an extensive targeted class of tryptamine-based molecules. The agreement for the license will provide access to large catalog of compounds that are complementary to Cybin’s preclinical assets and that strengthen the company’s drug-discovery and development platform to build future potential novel drug candidates. The agreement also supports Cybin’s broad intellectual property portfolio of innovative psychedelic-based molecules. According to…

Continue Reading

TuesdaySep 27, 2022 1:52 pm

BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Collaborates with EVERSANA(R) to Bring BEATdiabetes Solution to Market

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced its entry into a preliminary agreement with EVERSANA(R), a pioneer of next-gen commercial services to the global life sciences industry. The agreement covers the U.S. and all global sales and marketing of Nemaura’s diabetes management program, BEATdiabetes, which is based on Nemaura’s noninvasive glucose monitoring solution, proBEAT(TM). Nemaura and EVERSANA will collaborate to develop the optimal launch strategy for large-scale adoption of the program, including franchising and direct sales to self-insured corporate clients and health…

Continue Reading

TuesdaySep 27, 2022 11:39 am

BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Uplisting to Nasdaq Capital Market, Pricing of $5M Public Offering

Silo Pharma (NASDAQ: SILO) (formerly OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced pricing of an underwritten public offering of 1,000,000 shares of its common stock at a price to the public of $5.00 per share. Silo Pharma expects $5,000,000 in gross proceeds from the offering and intends to use the net proceeds for product development, marketing, working capital and general corporate purposes. In addition, a portion of the proceeds may also be used for acquisitions of complementary businesses, technologies or other assets. As a result of the offering, the company’s…

Continue Reading

TuesdaySep 27, 2022 10:47 am

BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC), New Investor Group Sign $3.67M Equity Investment Agreements

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, has entered into legally binding investment agreements with nine institutional and individual investors; the agreements outline an investment in the company of approximately $3.67 million. According to the announcement, the various shares purchase agreements outline plans for a private offering of $3.67 million earmarked to purchase 36.7 million of the company’s Class A shares; the company anticipates that the investment will be complete this month. “This equity investment is important to the company’s operations as well as research and…

Continue Reading

MondaySep 26, 2022 11:34 am

BioMedNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Issues Letter to Stockholders

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, today released a letter to stockholders from its Chief Executive Officer Dr. James Woody. In the letter, Dr. Woody discussed the company’s continued status to remain on track with clinical development plans. “Currently, we have an active clinical development program that includes phase 2a and phase 2b proof-of-concept data, which we believe demonstrates that anti-TNF therapy can prevent the progression of Dupuytren’s disease in its early stages, as well as plans for two additional phase 2 studies, one in frozen shoulder, which has recently commenced, and the other in post-operative cognitive…

Continue Reading

MondaySep 26, 2022 10:55 am

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Methodical Expansion of Its IP Portfolio

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced the filing of two new provisional patent applications. According to the update, one application, #63/405,786, is for the use of psilocybin for the treatment of patients with fibromyalgia and the other, #63/375,305, expands the IP related to the company’s development of TRP-8803. “Tryp is taking an innovative approach to expand treatment alternatives for patients suffering from nociplastic pain and eating disorders who haven’t had success with currently approved drugs,” said Jim Gilligan, chief executive officer of Tryp…

Continue Reading

FridaySep 23, 2022 2:40 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces 2022 Financial Results, Business Update

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today reported financial results for the fiscal year ended June 30, 2022. “In the final quarter of our fiscal 2022, as well as throughout the previous fiscal year, we have made important advancements in our pharmaceutical drug development programs, including expanding our phase 2 clinical trial for the treatment of symptoms related to epidermolysis bullosa to include adolescents, and initiating a research collaboration agreement to further screen cannabinoid analogs for potential therapeutic uses. As announced on Sept. 8, 2022, we have…

Continue Reading

FridaySep 23, 2022 1:28 pm

BioMedNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Closing Under Share Subscription Agreement, Appointment of New CFO

Mydecine (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), is a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD. The company today announced that, in connection with its previously disclosed common share subscription agreement with a third-party investor dated Aug. 26, 2022, and the subsequent filing of a shelf prospectus supplement in connection therewith on Sept. 7, 2022, it has closed the second tranche of the first issuance under the subscription agreement. Mydecine also announced the appointment of John Ross as its chief financial officer.…

Continue Reading